Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone
Mast cell tumors (MCTs) are common neoplasms in dogs, and treatments for these diseases include surgery, polychemotherapy and targeted therapy with tyrosine kinase inhibitors. This study aimed to evaluate the response and the adverse events of treatment with imatinib mesylate (IM) compared to conven...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/11/3/571 |
| _version_ | 1827660988433825792 |
|---|---|
| author | Thais Rodrigues Macedo Genilson Fernandes de Queiroz Thaís Andrade Costa Casagrande Pâmela Almeida Alexandre Paulo Eduardo Brandão Heidge Fukumasu Samanta Rios Melo Maria Lucia Zaidan Dagli Ana Carolina B. C. Fonseca Pinto Julia Maria Matera |
| author_facet | Thais Rodrigues Macedo Genilson Fernandes de Queiroz Thaís Andrade Costa Casagrande Pâmela Almeida Alexandre Paulo Eduardo Brandão Heidge Fukumasu Samanta Rios Melo Maria Lucia Zaidan Dagli Ana Carolina B. C. Fonseca Pinto Julia Maria Matera |
| author_sort | Thais Rodrigues Macedo |
| collection | DOAJ |
| description | Mast cell tumors (MCTs) are common neoplasms in dogs, and treatments for these diseases include surgery, polychemotherapy and targeted therapy with tyrosine kinase inhibitors. This study aimed to evaluate the response and the adverse events of treatment with imatinib mesylate (IM) compared to conventional therapy using vinblastine and prednisolone (VP) in canine cutaneous MCTs. Twenty-four dogs were included in the study; 13 animals were treated with IM and 11 with VP. Tumor tissue samples were submitted for histological diagnosis, grading and KIT immunostaining. The response to treatment was assessed by tomographic measurements according to VCOG criteria. Adverse events were classified according to VCOG-CTCAE criteria. The IM and VP groups had dogs with similar breeds, gender, ages, MCT localization, WHO stages and lymph node metastasis profiles. Most MCTs were grade 2/low and had KIT- patterns 2 and 3. The objective response rate (ORR) was significantly higher (30.79%) in the IM group then in VP group (9.09%). Adverse events (AE) in IM group were all grade 1, significantly different from VP. In conclusion, IM presented better ORR and less severe adverse events when compared to VP, representing a suitable option for the treatment of low-grade canine MCTs. |
| first_indexed | 2024-03-10T00:02:13Z |
| format | Article |
| id | doaj.art-530748cb526740ce851f92616d7a2414 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T00:02:13Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-530748cb526740ce851f92616d7a24142023-11-23T16:14:11ZengMDPI AGCells2073-44092022-02-0111357110.3390/cells11030571Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and PrednisoneThais Rodrigues Macedo0Genilson Fernandes de Queiroz1Thaís Andrade Costa Casagrande2Pâmela Almeida Alexandre3Paulo Eduardo Brandão4Heidge Fukumasu5Samanta Rios Melo6Maria Lucia Zaidan Dagli7Ana Carolina B. C. Fonseca Pinto8Julia Maria Matera9Department of Surgery, School of Veterinary Medicine and Animal Science, University of São Paulo, São Paulo 05508-010, BrazilDepartment of Animal Science, Federal Rural University of Semi-Arid, Mossoró 59625-900, BrazilMaster’s and Doctor’s Degree Program in Industrial Biotecnology at Positivo University, Curitiba 81280-330, BrazilDepartment of Preventive Veterinary Medicine and Animal Health, School of Veterinary Medicine and Animal Science, University of São Paulo, São Paulo 05508-010, BrazilDepartment of Preventive Veterinary Medicine and Animal Health, School of Veterinary Medicine and Animal Science, University of São Paulo, São Paulo 05508-010, BrazilLaboratory of Comparative and Translational Oncology (LOCT), Department of Veterinary Medicine, Faculty of Animal Science and Food Engineering, University of Sao Paulo, Pirassununga 13635-900, BrazilDepartment of Surgery, School of Veterinary Medicine and Animal Science, University of São Paulo, São Paulo 05508-010, BrazilLaboratory of Experimental and Comparative Oncology, Department of Pathology, School of Veterinary Medicine and Animal Science, University of São Paulo, São Paulo 05508-010, BrazilDepartment of Surgery, School of Veterinary Medicine and Animal Science, University of São Paulo, São Paulo 05508-010, BrazilDepartment of Surgery, School of Veterinary Medicine and Animal Science, University of São Paulo, São Paulo 05508-010, BrazilMast cell tumors (MCTs) are common neoplasms in dogs, and treatments for these diseases include surgery, polychemotherapy and targeted therapy with tyrosine kinase inhibitors. This study aimed to evaluate the response and the adverse events of treatment with imatinib mesylate (IM) compared to conventional therapy using vinblastine and prednisolone (VP) in canine cutaneous MCTs. Twenty-four dogs were included in the study; 13 animals were treated with IM and 11 with VP. Tumor tissue samples were submitted for histological diagnosis, grading and KIT immunostaining. The response to treatment was assessed by tomographic measurements according to VCOG criteria. Adverse events were classified according to VCOG-CTCAE criteria. The IM and VP groups had dogs with similar breeds, gender, ages, MCT localization, WHO stages and lymph node metastasis profiles. Most MCTs were grade 2/low and had KIT- patterns 2 and 3. The objective response rate (ORR) was significantly higher (30.79%) in the IM group then in VP group (9.09%). Adverse events (AE) in IM group were all grade 1, significantly different from VP. In conclusion, IM presented better ORR and less severe adverse events when compared to VP, representing a suitable option for the treatment of low-grade canine MCTs.https://www.mdpi.com/2073-4409/11/3/571c-KITimatinib mesylateimmunohistochemistrymast cell tumorprednisonevinblastine |
| spellingShingle | Thais Rodrigues Macedo Genilson Fernandes de Queiroz Thaís Andrade Costa Casagrande Pâmela Almeida Alexandre Paulo Eduardo Brandão Heidge Fukumasu Samanta Rios Melo Maria Lucia Zaidan Dagli Ana Carolina B. C. Fonseca Pinto Julia Maria Matera Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone Cells c-KIT imatinib mesylate immunohistochemistry mast cell tumor prednisone vinblastine |
| title | Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone |
| title_full | Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone |
| title_fullStr | Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone |
| title_full_unstemmed | Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone |
| title_short | Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone |
| title_sort | imatinib mesylate for the treatment of canine mast cell tumors assessment of the response and adverse events in comparison with the conventional therapy with vinblastine and prednisone |
| topic | c-KIT imatinib mesylate immunohistochemistry mast cell tumor prednisone vinblastine |
| url | https://www.mdpi.com/2073-4409/11/3/571 |
| work_keys_str_mv | AT thaisrodriguesmacedo imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone AT genilsonfernandesdequeiroz imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone AT thaisandradecostacasagrande imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone AT pamelaalmeidaalexandre imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone AT pauloeduardobrandao imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone AT heidgefukumasu imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone AT samantariosmelo imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone AT marialuciazaidandagli imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone AT anacarolinabcfonsecapinto imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone AT juliamariamatera imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone |